Baillie Gifford & Co
FATE icon

Baillie Gifford & Co’s Fate Therapeutics FATE Stock Holding History

Baillie Gifford & Co’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-372
Closed -$2.12K – 348
2023
Q1 		$2.12K Hold
372
– – ﹤0.01% 437
2022
Q4 		$3.75K Hold
372
– – ﹤0.01% 458
2022
Q3 		$8K Hold
372
– – ﹤0.01% 424
2022
Q2 		$9K Buy
+372
New +$10.3K ﹤0.01% 422

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Baillie Gifford & Co's FATE Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Fate Therapeutics (FATE) in Q2 2023, closing a stake of 372 shares — an estimated $2.12K sold.

Baillie Gifford & Co first reported a position in FATE in Q2 2022 and held it in 4 quarters. The position peaked at $9K in Q2 2022. 188 funds tracked by Wall St. Rank hold FATE as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Fate Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 372 Fate Therapeutics shares in Q2 2023, an estimated $2.12K.
  • Baillie Gifford & Co first reported a position in Fate Therapeutics in Q2 2022 and held it in 4 quarters.
  • Baillie Gifford & Co's Fate Therapeutics position peaked at $9K in Q2 2022.
  • 188 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.